News
Article
What We’re Reading: Amazon Pharmacy’s Insulin Discounts; Eris Variant COVID-19 Cases Increasing; DOJ Responds to COC Claims
Author(s):
Amazon’s online pharmacy aims to improve access and price transparency for insulin; cases of the COVID-19 Eris variant are increasing globally; the Department of Justice (DOJ) responds to pushbacks of Medicare's drug price negotiation program from the Chamber of Commerce (COC).
Amazon Pharmacy Automates Discount Coupons for Insulin and Diabetes Medicines
Amazon has introduced a new feature to its online pharmacy that automatically applies manufacturer-sponsored coupons to over 15 insulin and diabetes medicines, aiding patients in accessing discounts that were promised by major drug manufacturers, according to Reuters. The coupons are intended to reduce the cost of insulin to as low as $35 for a 1-month supply. The move comes in response to challenges patients faced in obtaining discounted insulin prices as advertised, with Amazon aiming to make the process more transparent and accessible for the 37 million Americans with diabetes.
WHO Designates Eris "Variant of Interest," Highlighting Potential Mutations
The World Health Organization (WHO) is closely monitoring the new COVID-19 variant called EG.5, also known as Eris, which is becoming more prevalent in countries like China and the United States, according to CNBC. Classified as a "variant of interest," EG.5 is being observed for any mutations that could have an impact on its severity or transmissibility. Although the variant has shown increased prevalence and immune escape properties, the WHO states there have been no reported changes in disease severity associated with EG.5. Vaccine manufacturers like Moderna, Pfizer, and Novavax are preparing to release reformulated vaccines targeting the XBB variants, to which EG.5 is related.
DOJ Counters Bid to Block Medicare Drug Price Negotiation Program
The Department of Justice (DOJ) has responded to the Chamber of Commerce's request for an injunction to halt implementation of the Medicare Drug Price Negotiation Program, according to The Hill. The Chamber had filed a motion claiming that the program would harm businesses and patients in the United States, but the DOJ's response argues that the Chamber lacks standing to file the lawsuit and asserts that pausing the program would be detrimental to the public's interest. The DOJ also highlights that the negotiated prices' impact on companies won't be felt until 2026 and that the case can be fully litigated by then and emphasizes that the program aims to control Medicare spending and make drugs more affordable for seniors.
